BEPSENTYZ Trademark

Trademark Overview


On Thursday, August 11, 2022, a trademark application was filed for BEPSENTYZ with the United States Patent and Trademark Office. The USPTO has given the BEPSENTYZ trademark a serial number of 97545156. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, November 5, 2024. This trademark is owned by Glaxo Group Limited. The BEPSENTYZ trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
bepsentyz

General Information


Serial Number97545156
Word MarkBEPSENTYZ
Filing DateThursday, August 11, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2024

Trademark Statements


Goods and ServicesVaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 31, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB

Trademark Events


Event DateEvent Description
Wednesday, May 31, 2023SUSPENSION LETTER WRITTEN
Monday, August 15, 2022NEW APPLICATION ENTERED
Wednesday, August 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 30, 2023ASSIGNED TO EXAMINER
Wednesday, May 31, 2023LETTER OF SUSPENSION E-MAILED
Wednesday, May 31, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, July 12, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, July 12, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, July 12, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 27, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, January 10, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Wednesday, February 7, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 21, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 7, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 5, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2024SOU EXTENSION 1 GRANTED
Tuesday, November 5, 2024SOU EXTENSION 1 FILED